Only 8% of new cancer drug authorisations are for children – this needs to improve

The report, From patent to patient – analysing access to innovative cancer drugs, looks at how efficiently new cancer drugs licensed in Europe reach NHS patients here in the UK. The main findings were:

    – Only 8% of new drug authorisations are for children
    – Cancers of unmet need, such as brain, womb, bladder, oesophageal, liver and pancreatic are missing out on advances
    – Leaps forward in cancer research mean many more new drugs
    – Average time from patent to NHS patient increased by more than a year
    – NICE is not doing enough to ensure most innovative treatments reach patients.


    Read all the latest fundraising news, charity news and commentary on childhood cancer.

    Pilot findings published in an article in the Journal of Clinical Oncology.
    Our ‘Say My Name’ Season’s Greeting’s card are now available to buy.